Abstract
The identification of novel molecular targets has paved the way for new treatment options in cancer patients. A number of agents targeting molecules that are crucial both for the tumor and its microenvironment have already been approved by the U.S. Food and Drug Administration for clinical use. The monoclonal antibodies and the small molecule kinase inhibitors constitute two major classes of targeted therapeutic agents, which have apparently different mechanisms of action, toxicity profiles, routes of administration, timing and dosing. Moreover, individual differences in genes regulating the distribution and metabolism of targeted agents evidently influence treatment outcomes. Data regarding the immune- and tumor microenvironment-modulatory properties of most of these agents are either obscure or controversial, as well. Therefore, preclinical animal and human studies that aim to identify the immunological, biological and the pharmacological properties of these novel classes of agents that also employ recent developments in pharmacogenomics and proteomics are warranted.
Keywords: Targeted therapy, targeted therapeutic agents, small molecule kinase inhibitors, therapeutic monoclonal antibodies, anti-tumor immune responses, angiogenesis, EGF, VEGF, sorafenib, sunitinib.
Protein & Peptide Letters
Title:Therapeutic Proteins in Tumors and Targeted Therapeutic Agents for Cancer Patients
Volume: 20 Issue: 12
Author(s): S. Altug Kesikli and Saadettin Kilickap
Affiliation:
Keywords: Targeted therapy, targeted therapeutic agents, small molecule kinase inhibitors, therapeutic monoclonal antibodies, anti-tumor immune responses, angiogenesis, EGF, VEGF, sorafenib, sunitinib.
Abstract: The identification of novel molecular targets has paved the way for new treatment options in cancer patients. A number of agents targeting molecules that are crucial both for the tumor and its microenvironment have already been approved by the U.S. Food and Drug Administration for clinical use. The monoclonal antibodies and the small molecule kinase inhibitors constitute two major classes of targeted therapeutic agents, which have apparently different mechanisms of action, toxicity profiles, routes of administration, timing and dosing. Moreover, individual differences in genes regulating the distribution and metabolism of targeted agents evidently influence treatment outcomes. Data regarding the immune- and tumor microenvironment-modulatory properties of most of these agents are either obscure or controversial, as well. Therefore, preclinical animal and human studies that aim to identify the immunological, biological and the pharmacological properties of these novel classes of agents that also employ recent developments in pharmacogenomics and proteomics are warranted.
Export Options
About this article
Cite this article as:
Kesikli Altug S. and Kilickap Saadettin, Therapeutic Proteins in Tumors and Targeted Therapeutic Agents for Cancer Patients, Protein & Peptide Letters 2013; 20 (12) . https://dx.doi.org/10.2174/092986652012131112123040
DOI https://dx.doi.org/10.2174/092986652012131112123040 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Use of the Inhibitory Receptors for Modulating the Immune Responses
Current Pharmaceutical Design Phyto-Phospholipid Complexation as a Novel Drug Delivery System for Management of Cancer with Better Bioavailability: Current Perspectives and Future Prospects
Anti-Cancer Agents in Medicinal Chemistry New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is)
Current Medicinal Chemistry Tyrosine Kinase Inhibitors
Current Cancer Drug Targets Combined Cancer Therapy with Non-Conventional Drugs: All Roads Lead to AMPK
Mini-Reviews in Medicinal Chemistry Molecular Imaging in Optical Coherence Tomography
Current Molecular Imaging (Discontinued) Peroxynitrite-Mediated Structural Changes in Histone H2A: Biochemical and Biophysical Analysis
Protein & Peptide Letters The Linkage Between Inflammation and Immune Tolerance: Interfering with Inflammation in Cancer
Current Cancer Drug Targets Role of Natural Phenolic Compounds in Cancer Chemoprevention via Regulation of the Cell Cycle
Current Pharmaceutical Biotechnology STAT-3 Inhibitors: State of the Art and New Horizons for Cancer Treatment
Current Medicinal Chemistry Modulation of Photosensitization Processes for an Improved Targeted Photodynamic Therapy
Current Medicinal Chemistry The Potential of 11C-acetate PET for Monitoring the Fatty Acid Synthesis Pathway in Tumors
Current Pharmaceutical Biotechnology Antihyperlipidemic and Antiobesity Potential of <i>Aquilaria agallocha</i> and <i>Borago officinalis</i> in Fixed-Dose Combination; A Contingent Probe with Atorvastatin and Orlistat
Current Bioactive Compounds VEGF in Tumor Progression and Targeted Therapy
Current Cancer Drug Targets Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies
Current Cancer Drug Targets Risk Factors for Serious Adverse Effects of Thiopurines in Patients with Crohn’s Disease
Current Drug Safety The Role of JNK Signalling in Responses to Oxidative DNA Damage
Current Drug Targets Malignant Mesothelioma Resistance to Apoptosis: Recent Discoveries and their Implication for Effective Therapeutic Strategies
Current Medicinal Chemistry Early Palliative Care in Advanced Oncologic and Non-Oncologic Chronic Diseases: A Systematic Review of Literature
Reviews on Recent Clinical Trials Biological Activity of Carotenoids: Its Implications in Cancer Risk and Prevention
Current Pharmaceutical Biotechnology